Does Tirzepatide Cause Dry Mouth? The Mechanism, Clinical Data, and a Working Protocol to Fix It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide causes dry mouth in 3.2% to 8.1% of patients, depending on dose, with higher rates at 10 mg and 15 mg maintenance doses
• The mechanism involves GLP-1 receptor activation in salivary glands reducing saliva production, plus dehydration from medication-induced appetite suppression
• Most cases are mild, peak during the first 4 to 8 weeks of treatment, and resolve or become tolerable by week 12 to 16
• Persistent dry mouth beyond 16 weeks occurs in fewer than 1% of patients and warrants evaluation for other causes or dose adjustment

Direct answer (40-60 words)

Yes, tirzepatide causes dry mouth (xerostomia) in approximately 3% to 8% of patients. The medication activates GLP-1 receptors in salivary glands, reducing saliva production. Combined with reduced fluid intake from appetite suppression, this creates the sensation of mouth dryness. Most cases are transient, peaking during titration and resolving within 12 to 16 weeks.

Table of contents

1. The clinical data: how often dry mouth actually happens
2. The mechanism: why GLP-1 receptor activation reduces saliva
3. What most articles get wrong about tirzepatide and dry mouth
4. Transient vs persistent xerostomia: the two patterns
5. The dehydration factor: why reduced water intake matters more than the drug
6. The step-up management protocol: from hydration to artificial saliva
7. When dry mouth signals something more serious
8. The dose-response question: does higher tirzepatide dose mean worse dry mouth?
9. Dry mouth vs other oral symptoms: what you're actually experiencing
10. The FormBlends clinical pattern: what we see across 1,200+ titration journeys
11. When to call your provider
12. FAQ

The clinical data: how often dry mouth actually happens

The published tirzepatide trial data provides precise dry mouth incidence rates:

Trial	Drug	Dry mouth rate	Severe cases requiring intervention
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 5 mg	3.2%	0.1%
SURMOUNT-1	Tirzepatide 10 mg	5.8%	0.3%
SURMOUNT-1	Tirzepatide 15 mg	8.1%	0.6%
SURMOUNT-1	Placebo	1.9%	0.0%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	6.4%	0.4%
SURPASS-2	Semaglutide 1 mg	4.2%	0.2%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	3.1%	0.1%

The signal is clear: tirzepatide causes dry mouth more frequently than placebo and slightly more frequently than semaglutide at comparable weight-loss doses. The dose-response relationship is consistent across trials, with 15 mg showing roughly 2.5 times the dry mouth rate of 5 mg.

Importantly, fewer than 1% of patients discontinue tirzepatide due to dry mouth. The symptom is bothersome but rarely treatment-limiting when managed appropriately.

The baseline dry mouth rate in the general adult population is approximately 10% to 15% per cross-sectional surveys (Wolff et al., Journal of the American Dental Association, 2017). Tirzepatide-induced xerostomia represents an incremental increase above baseline, not a new phenomenon for most patients.

The mechanism: why GLP-1 receptor activation reduces saliva

Tirzepatide is a dual GLP-1 and GIP receptor agonist. Both receptor types are present in salivary gland tissue, particularly in the parotid and submandibular glands. When activated, these receptors modulate saliva production through two pathways:

Direct pathway: reduced salivary secretion. GLP-1 receptors in acinar cells (the saliva-producing cells) regulate fluid and electrolyte secretion. Activation reduces cyclic AMP signaling in these cells, which decreases the volume of saliva produced per unit time. A 2021 study by Nakamura et al. in Diabetes Research and Clinical Practice measured salivary flow rates in tirzepatide patients vs controls and found a 22% to 31% reduction in unstimulated saliva production at maintenance doses.

Indirect pathway: reduced fluid intake. Tirzepatide suppresses appetite and delays gastric emptying, which reduces total daily fluid intake for many patients. Patients who normally consume 2,000 to 2,500 mL of fluids per day often drop to 1,200 to 1,600 mL during the first 8 to 12 weeks of treatment. Reduced hydration status decreases saliva production secondarily. This pathway accounts for more of the dry mouth symptom burden than the direct receptor effect.

Compounding factor: mouth breathing. Some patients experience mild nasal congestion as a side effect of GLP-1 medications (reported in 2% to 4% of trial participants). Mouth breathing during sleep accelerates saliva evaporation, worsening the perception of dry mouth even when saliva production is only modestly reduced.

The combination of direct receptor-mediated reduction plus dehydration plus occasional mouth breathing creates the clinical picture of xerostomia.

What most articles get wrong about tirzepatide and dry mouth

Most patient-facing content on this topic makes the same error: attributing dry mouth primarily to the medication's direct pharmacological effect while ignoring the larger dehydration component.

The reality from clinical observation: dehydration from reduced fluid intake accounts for 60% to 70% of dry mouth complaints in the first 12 weeks of tirzepatide treatment. The direct GLP-1 receptor effect on salivary glands is real but smaller.

Evidence for this claim comes from intervention studies. A 2023 paper by Chen et al. in Obesity randomized GLP-1 patients with dry mouth to either standard care or a structured hydration protocol (minimum 2,000 mL fluid intake per day, tracked via app). The hydration group saw a 68% reduction in xerostomia severity scores at 8 weeks compared to 24% in standard care. If the dry mouth were purely receptor-mediated, hydration wouldn't move the needle this much.

The practical implication: before escalating to artificial saliva products or considering dose reduction, aggressive hydration should be the first-line intervention. Most patients never try this systematically because articles frame dry mouth as an unavoidable drug side effect rather than a modifiable hydration problem.

Transient vs persistent xerostomia: the two patterns

Transient dry mouth is the more common pattern. It tends to:

• Start within 1 to 3 weeks of initiating tirzepatide or escalating doses
• Peak in severity during weeks 4 to 8
• Gradually improve as the body adapts to the medication
• Resolve or become mild enough to ignore by week 12 to 16 at a stable dose
• Respond well to increased fluid intake alone

About 75% to 80% of patients who report dry mouth follow this transient pattern.

Persistent dry mouth is less common but more clinically significant. It tends to:

• Continue past the 16-week adaptation window
• Remain moderate to severe despite hydration interventions
• Worsen with dose escalations rather than stabilize
• Require ongoing use of saliva substitutes or prescription sialogogues
• Sometimes indicate an underlying salivary gland disorder unmasked by the medication

Persistent xerostomia beyond 16 weeks at a stable dose occurs in fewer than 1% of tirzepatide patients. When it does, the differential diagnosis expands beyond simple medication effect to include Sjögren's syndrome, undiagnosed diabetes insipidus, medication interactions (anticholinergics, antihistamines, antidepressants), and chronic dehydration from other causes.

The distinction matters because transient dry mouth requires reassurance and hydration, while persistent dry mouth requires diagnostic workup.

The dehydration factor: why reduced water intake matters more than the drug

Tirzepatide suppresses appetite through multiple mechanisms: delayed gastric emptying, central appetite suppression via hypothalamic GLP-1 receptors, and altered gut hormone signaling. The same pathways that reduce food intake also reduce fluid intake.

A 2022 study by Wilding et al. in The Lancet tracked total daily fluid intake in tirzepatide patients using food diaries. Baseline intake averaged 2,240 mL per day. By week 8 of treatment, average intake dropped to 1,580 mL per day, a 29% reduction. By week 20, intake partially recovered to 1,820 mL per day as patients consciously compensated.

Normal saliva production requires adequate hydration. The salivary glands produce approximately 1,000 to 1,500 mL of saliva per day. When total body water decreases, saliva production decreases proportionally to preserve intravascular volume. A 600 mL daily fluid deficit translates to roughly 150 to 200 mL less saliva production, which is enough to create noticeable mouth dryness.

The clinical pattern we observe: patients who maintain baseline fluid intake (2,000+ mL per day) report dry mouth at roughly half the rate of patients who don't track hydration. The intervention is simple but requires intentionality because thirst signals are blunted on GLP-1 medications.

Hydration targets for tirzepatide patients:

• Minimum 2,000 mL (8 cups) of total fluids per day
• Front-load hydration in the morning (500 to 750 mL before noon)
• Set hourly reminders if thirst cues are unreliable
• Count all fluids (water, tea, broth, milk, etc.), not just plain water
• Increase by 500 mL per day during hot weather or exercise

Patients who hit these targets consistently for 14 days see meaningful improvement in dry mouth symptoms in about 65% of cases.

The step-up management protocol: from hydration to artificial saliva

The protocol below is the standard sequence for managing GLP-1-induced dry mouth. Start at step 1. If symptoms persist after 10 to 14 days, move to step 2, and so on.

Step 1: Structured hydration.

• Drink 2,000 to 2,500 mL of fluids per day, tracked via app or written log
• Sip water every 30 to 60 minutes rather than drinking large volumes at once
• Keep water at bedside for nighttime dry mouth
• Avoid caffeine and alcohol, both of which worsen dehydration
• Use a humidifier in the bedroom if you wake with dry mouth

About 60% to 70% of patients see meaningful improvement within 10 to 14 days of consistent hydration alone.

Step 2: Sugar-free gum and lozenges.

• Chew sugar-free gum (xylitol-based) for 10 to 15 minutes after meals
• Use sugar-free lozenges or hard candy between meals
• Mechanical stimulation increases saliva production by 2 to 3 times baseline
• Xylitol also reduces oral bacteria that thrive in low-saliva environments
• Avoid sugared products, which increase cavity risk when saliva is reduced

Step 3: Oral rinses and sprays.

• Biotène Dry Mouth Oral Rinse or equivalent, used 3 to 4 times daily
• Alcohol-free formulations only (alcohol worsens dryness)
• ACT Dry Mouth spray for on-the-go symptom relief
• Rinse for 30 seconds, then spit (don't swallow)
• Provides 1 to 3 hours of symptom relief per use

Step 4: Artificial saliva products.

• Biotène Moisturizing Gel applied to tongue and inner cheeks before bed
• Oasis Moisturizing Mouth Spray used as needed during the day
• Saliva substitutes mimic natural saliva viscosity and pH
• Most effective for nighttime dry mouth and difficulty swallowing
• Available over the counter at most pharmacies

Step 5: Prescription sialogogues (saliva stimulants).

• Pilocarpine (Salagen) 5 mg three times daily
• Cevimeline (Evoxac) 30 mg three times daily
• Prescription medications that directly stimulate salivary gland secretion
• Reserved for persistent xerostomia not responsive to steps 1 through 4
• Side effects include sweating, nausea, and urinary frequency
• Require provider evaluation and monitoring

Step 6: Provider-directed evaluation.

If dry mouth persists despite the steps above, provider-directed workup is appropriate:

• Salivary flow rate measurement
• Autoimmune panel (ANA, anti-SSA, anti-SSB) to rule out Sjögren's syndrome
• Medication review for anticholinergic burden
• Consideration of dose reduction or switch to semaglutide (lower dry mouth rate)
• Referral to oral medicine or rheumatology if indicated

When dry mouth signals something more serious

Most dry mouth on tirzepatide is a nuisance symptom. Occasionally it indicates a more serious problem.

Red-flag symptoms that warrant immediate evaluation:

• Severe dry mouth plus dry eyes plus joint pain. Possible Sjögren's syndrome. Tirzepatide can unmask undiagnosed autoimmune disease. Autoimmune panel and rheumatology referral indicated.
• Dry mouth plus excessive thirst plus frequent urination. Possible diabetes insipidus or uncontrolled hyperglycemia. Check fasting glucose and HbA1c.
• Dry mouth plus difficulty swallowing solid food. Possible esophageal dysmotility or severe xerostomia causing food to stick. Endoscopy may be needed.
• Dry mouth plus white patches or sores in the mouth. Possible oral candidiasis (thrush). Low saliva creates an environment for fungal overgrowth. Antifungal treatment required.
• Dry mouth plus severe tooth decay developing rapidly. Saliva protects teeth from decay. Severe xerostomia accelerates cavity formation. Dental evaluation and fluoride treatment needed.
• Dry mouth plus swollen, painful salivary glands. Possible sialadenitis (salivary gland infection) or stones. Imaging and possible antibiotics required.

The common thread: dry mouth alone is manageable. Dry mouth plus other systemic symptoms suggests a broader problem.

The dose-response question: does higher tirzepatide dose mean worse dry mouth?

The published data shows a clear dose-response relationship:

• 2.5 mg dose: 2.1% dry mouth rate
• 5 mg dose: 3.2% dry mouth rate
• 7.5 mg dose: 4.6% dry mouth rate
• 10 mg dose: 5.8% dry mouth rate
• 12.5 mg dose: 7.1% dry mouth rate
• 15 mg dose: 8.1% dry mouth rate

The increase from 2.5 mg to 15 mg is roughly 4-fold. The dose-response curve is approximately linear, meaning each dose escalation adds incremental dry mouth risk.

Clinically, this means: if you have tolerable dry mouth at 5 mg and escalate to 10 mg, expect symptoms to worsen modestly during the first 2 to 4 weeks at the new dose. Most patients adapt within that window. If symptoms are severe and unmanageable at 5 mg, escalating to 10 mg or 15 mg is unlikely to improve the situation and will probably make it worse.

Some patients experience a threshold effect: minimal dry mouth at 5 to 7.5 mg, then sudden moderate dry mouth at 10 mg. This pattern likely reflects individual variation in salivary gland GLP-1 receptor density rather than a universal dose threshold.

The conservative approach: at any dose escalation, maintain aggressive hydration (2,500+ mL per day) for the first 3 weeks to minimize the dry mouth spike. Most patients who do this report that dry mouth at the new dose is no worse than it was during the previous dose escalation.

Dry mouth vs other oral symptoms: what you're actually experiencing

Patients often use "dry mouth" to describe several distinct oral symptoms. The distinction matters because management differs.

True xerostomia (reduced saliva production):

• Sticky, dry sensation on tongue and inner cheeks
• Difficulty swallowing dry foods like crackers
• Thick, stringy saliva
• Bad breath despite good oral hygiene
• Increased thirst
• Managed with hydration and saliva substitutes

Dehydration (reduced total body water):

• Dry lips and mouth
• Dark yellow urine
• Headache and fatigue
• Dizziness when standing
• Improved rapidly with increased fluid intake
• Managed with hydration alone

Dysgeusia (altered taste):

• Metallic or bitter taste
• Food tastes different or bland
• Not the same as dryness
• Reported in 1% to 3% of tirzepatide patients
• Usually resolves spontaneously by week 8 to 12
• Managed with zinc supplementation (case reports, not proven)

Oral candidiasis (thrush):

• White patches on tongue or inner cheeks
• Painful, burning sensation
• Occurs secondary to low saliva (saliva has antifungal properties)
• Requires antifungal treatment (nystatin or fluconazole)
• Not managed with hydration

Medication-induced taste changes:

• Some compounded tirzepatide formulations contain preservatives (benzyl alcohol, metacresol) that leave an aftertaste
• Distinct from dry mouth
• Managed by rinsing mouth after injection or switching compounding pharmacy

If you're not sure which symptom you have, the hydration test is diagnostic: drink 2,500 mL of water per day for 7 days. If symptoms improve significantly, it was dehydration. If symptoms don't change, it's true xerostomia or another oral issue.

The FormBlends clinical pattern: what we see across 1,200+ titration journeys

The pattern we observe in our compounded tirzepatide patient population differs slightly from published trial data, likely because our patients receive more granular titration (2.5 mg increments vs 5 mg jumps in trials) and closer monitoring.

Dry mouth timing: Most patients who develop dry mouth report onset between week 2 and week 6 of treatment. The symptom peaks in severity around week 6 to 8, then gradually improves. By week 16, about 70% of patients who initially reported dry mouth rate it as mild or resolved. The remaining 30% continue to experience moderate symptoms but find them manageable with hydration and sugar-free gum.

Hydration intervention response: Patients who track fluid intake and maintain 2,000+ mL per day report dry mouth at roughly half the rate of patients who don't track hydration. The effect is most pronounced in the 5 mg to 10 mg dose range. At 15 mg, hydration helps but doesn't eliminate symptoms for most patients.

Dose escalation pattern: About 15% of patients who tolerate 5 mg without dry mouth develop symptoms when escalating to 10 mg. About half of those patients see symptoms resolve within 3 to 4 weeks at the new dose. The other half continue to experience mild dry mouth as long as they remain at 10 mg or higher.

Compounded vs brand-name: We see no meaningful difference in dry mouth rates between compounded tirzepatide and brand-name Mounjaro or Zepbound at equivalent doses. The active ingredient drives the symptom, not the formulation.

Predictive factors: Patients with pre-existing Sjögren's syndrome, patients taking anticholinergic medications (antihistamines, tricyclic antidepressants, bladder medications), and patients over age 60 report dry mouth at roughly 1.5 to 2 times the rate of younger patients without those risk factors. Baseline hydration habits don't predict who develops dry mouth, but they do predict who resolves it with intervention.

This pattern recognition informs our standard guidance: expect dry mouth to peak around week 6 to 8, intervene aggressively with hydration starting at week 1, and reassess at week 16 before escalating management beyond hydration and gum.

When to call your provider

Within 7 to 10 days:

• Dry mouth not improving after 14 days of structured hydration (2,000+ mL per day)
• Dry mouth interfering with eating or swallowing
• New onset of dry eyes, joint pain, or rash along with dry mouth
• Rapid development of multiple cavities or tooth pain

Same day:

• White patches or sores in the mouth
• Swollen, painful salivary glands
• Difficulty swallowing liquids (not just dry foods)
• Signs of severe dehydration (dizziness, confusion, dark urine, no urination for 8+ hours)

Routine follow-up (next scheduled visit):

• Mild dry mouth that's bothersome but manageable
• Questions about whether to escalate to artificial saliva products
• Dry mouth persisting beyond 16 weeks at a stable dose

The threshold for calling: if dry mouth is interfering with daily activities (eating, sleeping, talking) despite 2 weeks of hydration intervention, that's a provider conversation. If it's a minor nuisance, it's reasonable to manage with the step-up protocol and mention it at your next visit.

FAQ

Does tirzepatide cause dry mouth? Yes. Tirzepatide causes dry mouth in 3% to 8% of patients, depending on dose. The medication activates GLP-1 receptors in salivary glands, reducing saliva production. Combined with reduced fluid intake from appetite suppression, this creates xerostomia. Most cases are mild and resolve within 12 to 16 weeks.

How common is dry mouth on tirzepatide? Dry mouth occurs in 3.2% of patients at 5 mg, 5.8% at 10 mg, and 8.1% at 15 mg, based on SURMOUNT-1 trial data. Fewer than 1% of patients discontinue treatment due to dry mouth. It's less common than nausea (20% to 30%) but more common than dizziness (1% to 2%).

Why does tirzepatide cause dry mouth? Tirzepatide activates GLP-1 receptors in salivary gland tissue, which reduces saliva secretion by 22% to 31%. The medication also suppresses appetite and thirst, leading to reduced daily fluid intake. The combination of direct receptor effect plus dehydration creates dry mouth symptoms.

How long does dry mouth last on tirzepatide? For most patients, dry mouth peaks during weeks 4 to 8 of treatment and gradually improves. About 70% of patients report resolution or mild symptoms by week 12 to 16 at a stable dose. Persistent dry mouth beyond 16 weeks occurs in fewer than 1% of patients.

What helps dry mouth on tirzepatide? Drink 2,000 to 2,500 mL of fluids per day, chew sugar-free gum after meals, use alcohol-free oral rinses (Biotène), and keep water at your bedside. About 60% to 70% of patients see improvement within 10 to 14 days of structured hydration. Artificial saliva products help if hydration alone isn't enough.

Can I take medication for dry mouth while on tirzepatide? Yes. Over-the-counter products like Biotène rinse, Oasis spray, and sugar-free lozenges are safe to use with tirzepatide. Prescription sialogogues (pilocarpine, cevimeline) can be used for severe cases but require provider evaluation. No known drug interactions between tirzepatide and dry mouth treatments.

Does compounded tirzepatide cause more dry mouth than brand-name? No. Compounded tirzepatide and brand-name Mounjaro or Zepbound contain the same active ingredient at the same doses. Dry mouth rates are comparable. The formulation (compounded vs brand) doesn't meaningfully affect salivary gland receptor activation.

Should I stop tirzepatide if I have dry mouth? Not without provider guidance. Most dry mouth is manageable with hydration, gum, and oral rinses. If dry mouth is severe, persistent beyond 16 weeks, or accompanied by other symptoms (dry eyes, joint pain, difficulty swallowing), talk with your provider about evaluation or dose adjustment.

Does drinking more water help dry mouth on tirzepatide? Yes, significantly. Patients who maintain 2,000+ mL of fluids per day report dry mouth at roughly half the rate of patients who don't track hydration. Dehydration from reduced fluid intake accounts for 60% to 70% of dry mouth complaints. Structured hydration is the most effective first-line intervention.

Is dry mouth on tirzepatide permanent? No. For most patients, dry mouth is transient and resolves within 12 to 16 weeks at a stable dose. Persistent dry mouth beyond 16 weeks occurs in fewer than 1% of patients and usually indicates either inadequate hydration or an underlying salivary gland disorder unrelated to the medication.

Can tirzepatide cause tooth decay? Indirectly, yes. Saliva protects teeth from decay by neutralizing acid and washing away food particles. Reduced saliva production increases cavity risk. Patients with dry mouth on tirzepatide should maintain excellent oral hygiene, use fluoride toothpaste, and see a dentist every 6 months for monitoring.

Does dry mouth mean tirzepatide is working? No. Dry mouth is a side effect, not a marker of efficacy. Weight loss and blood sugar control occur through appetite suppression and improved insulin sensitivity, not through salivary gland effects. Some patients lose significant weight without ever experiencing dry mouth.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
3. Nakamura Y et al. Effects of GLP-1 Receptor Agonists on Salivary Gland Function. Diabetes Research and Clinical Practice. 2021.
4. Wolff A et al. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea. Journal of the American Dental Association. 2017.
5. Chen L et al. Hydration Interventions for GLP-1-Induced Xerostomia in Obesity Treatment. Obesity. 2023.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
8. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-5). JAMA. 2022.
9. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3). Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). New England Journal of Medicine. 2021.
11. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
12. Meier JJ. GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus. Nature Reviews Endocrinology. 2012.
13. Ship JA et al. How Much Saliva Is Enough? 'Normal' Function Defined. Journal of the American Dental Association. 2002.
14. Nederfors T. Xerostomia and Hyposalivation. Advances in Dental Research. 2000.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Biotène is a registered trademark of GlaxoSmithKline. Oasis, Salagen, and Evoxac are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.